Mark J. Ratain to Aged
This is a "connection" page, showing publications Mark J. Ratain has written about Aged.
Connection Strength
2.205
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
Score: 0.046
-
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
Score: 0.043
-
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 08; 35(4):471-477.
Score: 0.042
-
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10.
Score: 0.037
-
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
Score: 0.035
-
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):68-75.
Score: 0.035
-
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
Score: 0.031
-
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84.
Score: 0.029
-
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
Score: 0.028
-
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
Score: 0.028
-
A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
Score: 0.027
-
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2010 Mar; 87(3):303-10.
Score: 0.026
-
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
Score: 0.025
-
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009 Apr 10; 27(11):1800-5.
Score: 0.024
-
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
Score: 0.024
-
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.
Score: 0.023
-
Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402.
Score: 0.023
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
Score: 0.023
-
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21):3055-60.
Score: 0.022
-
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9.
Score: 0.021
-
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 04; 95(5):581-6.
Score: 0.020
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
Score: 0.020
-
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006 Jan; 57(2):199-206.
Score: 0.019
-
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.
Score: 0.019
-
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65.
Score: 0.019
-
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7.
Score: 0.018
-
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res. 2004 Dec 15; 10(24):8325-31.
Score: 0.018
-
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov; 22(4):449-58.
Score: 0.018
-
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
Score: 0.018
-
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 01; 10(21):7244-51.
Score: 0.018
-
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Nov; 54(5):377-84.
Score: 0.018
-
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
Score: 0.018
-
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-ß2 levels in metastatic colorectal cancer patients (Alliance). BMC Genomics. 2024 May 14; 25(1):473.
Score: 0.017
-
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec; 14(12):1783-90.
Score: 0.017
-
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7.
Score: 0.016
-
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. Med Oncol. 2003; 20(1):7-12.
Score: 0.016
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.016
-
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
Score: 0.015
-
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
Score: 0.015
-
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res. 2002 Apr; 8(4):1042-8.
Score: 0.015
-
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402.
Score: 0.015
-
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. Br J Cancer. 2002 Feb 12; 86(4):534-9.
Score: 0.015
-
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
Score: 0.015
-
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol. 2001 Dec; 12(12):1743-7.
Score: 0.015
-
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274.
Score: 0.015
-
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
Score: 0.015
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.014
-
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
Score: 0.014
-
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
Score: 0.014
-
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
Score: 0.014
-
Patient insights on features of an effective pharmacogenomics patient portal. Pharmacogenet Genomics. 2020 12; 30(9):191-200.
Score: 0.014
-
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 01 01; 27(1):267-275.
Score: 0.014
-
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020 09; 108(3):625-634.
Score: 0.013
-
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
Score: 0.013
-
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul; 18(14):2780-7.
Score: 0.013
-
A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol. 2000 Jun; 23(3):297-300.
Score: 0.013
-
Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther. 2020 08; 108(2):368-376.
Score: 0.013
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.013
-
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB. 2000 May-Jun; 22(3):6-14.
Score: 0.013
-
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. AAPS J. 2020 03 17; 22(3):59.
Score: 0.013
-
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. Clin Pharmacol Ther. 2020 06; 107(6):1383-1393.
Score: 0.013
-
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000; 45(6):489-94.
Score: 0.013
-
Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal. Clin Transl Sci. 2020 01; 13(1):78-87.
Score: 0.013
-
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
Score: 0.013
-
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Cancer. 1999 Aug 01; 86(3):528-32.
Score: 0.013
-
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenet Genomics. 2019 08; 29(6):123-131.
Score: 0.013
-
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924.
Score: 0.012
-
Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640.
Score: 0.012
-
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Clin Cancer Res. 1999 Jun; 5(6):1325-30.
Score: 0.012
-
Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing. Pharmacogenet Genomics. 2019 02; 29(2):23-30.
Score: 0.012
-
Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep. 2018 11 05; 8(1):16332.
Score: 0.012
-
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther. 2019 03; 105(3):738-745.
Score: 0.012
-
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Med. 2018 11; 7(11):5478-5487.
Score: 0.012
-
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol. 1998 Oct; 16(10):3302-9.
Score: 0.012
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.012
-
Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? J Clin Oncol. 2018 08 20; 36(24):2483-2491.
Score: 0.012
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.012
-
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744.
Score: 0.012
-
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050.
Score: 0.011
-
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. Eur Urol Focus. 2019 05; 5(3):416-424.
Score: 0.011
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.011
-
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7.
Score: 0.011
-
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol. 1997 Aug; 8(8):807-9.
Score: 0.011
-
Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation. Pharmacogenet Genomics. 2017 05; 27(5):179-189.
Score: 0.011
-
Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve. 1997 Jan; 20(1):83-91.
Score: 0.010
-
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
Score: 0.010
-
Mineralocorticoid insufficiency due to suramin therapy. Cancer. 1996 Dec 01; 78(11):2411-20.
Score: 0.010
-
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 01; 18(1):35-42.
Score: 0.010
-
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 02 01; 123(3):476-484.
Score: 0.010
-
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose. J Clin Oncol. 1996 Sep; 14(9):2622-3.
Score: 0.010
-
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. Cancer. 1996 Jun 01; 77(11):2308-12.
Score: 0.010
-
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
Score: 0.010
-
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
Score: 0.010
-
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
Score: 0.010
-
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol. 1996 Jan; 14(1):188-95.
Score: 0.010
-
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol. 1995 Sep; 13(9):2196-207.
Score: 0.010
-
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
Score: 0.009
-
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). J Natl Cancer Inst. 2015 Oct; 107(10).
Score: 0.009
-
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb; 16(1):54-9.
Score: 0.009
-
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
Score: 0.009
-
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69.
Score: 0.009
-
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemother Pharmacol. 1995; 36(3):204-10.
Score: 0.009
-
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
Score: 0.009
-
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2).
Score: 0.009
-
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015 Apr 01; 121(7):1025-31.
Score: 0.009
-
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014 Nov; 78(5):1005-13.
Score: 0.009
-
UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):94-104.
Score: 0.009
-
Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994 Oct 01; 74(7):1965-73.
Score: 0.009
-
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol. 2014 Nov; 74(5):927-38.
Score: 0.009
-
A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994 Jul 01; 74(1):168-73.
Score: 0.009
-
The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer. 2014 Oct 15; 120(20):3245-53.
Score: 0.009
-
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
Score: 0.009
-
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 15; 20(8):2205-14.
Score: 0.009
-
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
Score: 0.009
-
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res. 1994 Jan 01; 54(1):114-9.
Score: 0.009
-
Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther. 1993 Oct; 54(4):421-9.
Score: 0.008
-
Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther. 2013 Oct; 347(1):181-92.
Score: 0.008
-
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul; 23(7):374-81.
Score: 0.008
-
Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
Score: 0.008
-
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
Score: 0.008
-
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer. 1993 Apr 01; 71(7):2371-6.
Score: 0.008
-
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. Cancer Res. 1993 Mar 15; 53(6):1293-6.
Score: 0.008
-
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33.
Score: 0.008
-
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemother Pharmacol. 1993; 32(5):347-52.
Score: 0.008
-
Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012 Dec 29; 12:481.
Score: 0.008
-
Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. J Clin Oncol. 1992 Nov; 10(11):1821.
Score: 0.008
-
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109.
Score: 0.008
-
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991 Nov; 9(11):2021-6.
Score: 0.007
-
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 Aug; 9(8):1480-6.
Score: 0.007
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.007
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
Score: 0.007
-
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer. 2010 Jul; 46(11):2097-103.
Score: 0.007
-
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos. 2010 Jan; 38(1):32-9.
Score: 0.006
-
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs. 2011 Jun; 29(3):481-8.
Score: 0.006
-
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics. 2009 Jul; 10(7):1139-46.
Score: 0.006
-
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14.
Score: 0.006
-
Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Cancer. 1988 Dec 01; 62(11):2420-4.
Score: 0.006
-
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
Score: 0.006
-
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol. 1988 Nov; 6(11):1714-21.
Score: 0.006
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.006
-
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J. 2009 Feb; 9(1):49-60.
Score: 0.006
-
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol. 2009 Apr; 63(5):793-8.
Score: 0.006
-
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
Score: 0.006
-
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov; 70(5):1412-7.
Score: 0.006
-
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol. 2007 Aug 10; 25(23):3488-94.
Score: 0.005
-
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun 01; 13(11):3302-11.
Score: 0.005
-
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007 Feb 15; 13(4):1246-52.
Score: 0.005
-
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol. 2007 Feb 10; 25(5):548-54.
Score: 0.005
-
Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther. 1987 Jan; 41(1):61-7.
Score: 0.005
-
The role of interferon in the treatment of hairy cell leukemia. Semin Oncol. 1986 Sep; 13(3 Suppl 2):21-8.
Score: 0.005
-
Phase I and pharmacological study of vinblastine by prolonged continuous infusion. Cancer Res. 1986 Sep; 46(9):4827-30.
Score: 0.005
-
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8.
Score: 0.005
-
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006 Apr 20; 24(12):1846-51.
Score: 0.005
-
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genomics. 2006 Feb; 16(2):79-86.
Score: 0.005
-
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6.
Score: 0.005
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.005
-
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
Score: 0.005
-
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
Score: 0.005
-
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
Score: 0.004
-
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.
Score: 0.004
-
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004 Apr 15; 22(8):1439-46.
Score: 0.004
-
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
Score: 0.004
-
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs. 2004 Jan; 22(1):83-9.
Score: 0.004
-
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther. 2003 Jun; 73(6):566-74.
Score: 0.004
-
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6.
Score: 0.004
-
Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
Score: 0.004
-
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
Score: 0.004
-
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002 Aug; 50(2):121-6.
Score: 0.004
-
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84.
Score: 0.003
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
Score: 0.003
-
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol. 1998 Oct; 9(10):1085-90.
Score: 0.003
-
Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
Score: 0.003
-
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73.
Score: 0.003
-
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. J Clin Oncol. 1998 Jun; 16(6):2032-7.
Score: 0.003
-
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9.
Score: 0.003
-
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial. Cancer. 1998 Apr 01; 82(7):1352-8.
Score: 0.003
-
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
Score: 0.003
-
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34.
Score: 0.003
-
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
Score: 0.003
-
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405.
Score: 0.003
-
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25.
Score: 0.003
-
Keratoacanthomas and skin neoplasms associated with suramin therapy. Arch Dermatol. 1996 Jan; 132(1):96-8.
Score: 0.002
-
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7.
Score: 0.002
-
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704.
Score: 0.002
-
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995 May; 13(5):1062-72.
Score: 0.002
-
A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther. 1995 Mar; 57(3):325-34.
Score: 0.002
-
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
Score: 0.002
-
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72.
Score: 0.002
-
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986. Leuk Lymphoma. 1994; 14 Suppl 1:89-93.
Score: 0.002
-
Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14.
Score: 0.002
-
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst. 1993 Aug 18; 85(16):1319-26.
Score: 0.002
-
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. Ann Oncol. 1993 Aug; 4(7):591-5.
Score: 0.002
-
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
Score: 0.002
-
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8.
Score: 0.002
-
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol. 1992 Nov; 10(11):1810-6.
Score: 0.002
-
Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986. Leukemia. 1992 Nov; 6(11):1177-80.
Score: 0.002
-
Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst. 1992 Jan 15; 84(2):98-103.
Score: 0.002
-
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
Score: 0.002
-
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8.
Score: 0.002
-
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol. 1991; 28(1):69-73.
Score: 0.002
-
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. J Natl Cancer Inst. 1989 Aug 02; 81(15):1172-4.
Score: 0.002
-
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther. 1989 Apr; 45(4):340-7.
Score: 0.002
-
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients. J Clin Oncol. 1987 Dec; 5(12):1968-76.
Score: 0.001
-
Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia. Semin Oncol. 1987 Jun; 14(2 Suppl 2):13-7.
Score: 0.001
-
Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. Cancer Treat Rep. 1986 Sep; 70(9):1081-4.
Score: 0.001
-
Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol. 1986 Jun; 4(6):900-5.
Score: 0.001
-
Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell leukemia. Am J Clin Pathol. 1986 Feb; 85(2):194-201.
Score: 0.001